Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Endometrial01
2023-508056-19-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in endometrial cancer (EC) comparing Trastuzumab deruxtecan + rilvegostomig, Trastuzumab deruxtecan + pembrolizumab and Chemotherapy + pembrolizumab (3 arms). Primary endpoint: Progression-free survival by BICR. Planned start Oct 2025; status: authorised.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2023-508056-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508056-19-00.